Category Archives: Specialty HUBs

IntegriChain’s Growth Drives Executive Promotions and Blue Fin Group Acquisition

IntegriChain acquisition of Blue Fin Group expands its commercialization capabilities and strengthens the company’s market access expertise

Recent Activities Position AscellaHealth As a Leader in Specialty Pharmaceutical Services

AscellaHealth recently announced a comprehensive suite of Specialty Pharmacy (SP) services, including pre-commercialization, outsourced market access, wholesale, 3PL, limited distribution drug (LDD) fulfillment, and custom Patient Support and HUB Services

OWP Pharmaceuticals and EVERSANA Announce Commercialization Partnership

OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders

RxLightning and Oncospark Partner Simplifying Oncology Medication Enrollment and Prior Authorization

RxLightning and Oncospark partner to create a platform that streamlines the specialty medication enrollment and prior authorization process for oncology patients

Trinity Life Sciences Expanding Life Sciences Commercialization Capabilities

Trinity Life Sciences (Trinity) has since grown to comprise a global team of advisors, technical experts, data integrators, and technology innovators. Trinity’s vision is to be the premier global life sciences commercialization partner, empowering clients to deliver life-changing therapies to patients

Syneos Health Increases Data Analytics Capabilities with RxDataScience Acquisition

Syneos Health recently announced the acquisition of RxDataScience, a leading healthcare-focused data analytics, data management and artificial intelligence (AI) company

Veradigm and CareMetx Partner to Optimize Specialty Medication Access

Many hub service providers and other companies develop patient support platforms to offer patient-centric capabilities in order to provide better services that improve patient outcomes

Indegene Acquires Medical Marketing Economics (MME)

Indegene has acquired market-access advisory Medical Marketing Economics (MME) for $10 million, as it seeks to bolster its biopharma pricing and reimbursement capabilities